We’re proud to have 4 abstracts accepted for publication for the 2017 ASCO Annual Meeting. Educating oncologists and empowering cancer patients in the 21st century means delivering precision education that supports precision medicine.
We hope you’ll take some time to learn more about how our precision education platform supports precision medicine.
- New and emerging therapies for relapse/refractory multiple myeloma: Impact of education on practice behaviors (Abstract Number: e18096) An education activity focused on new and emerging therapies for RRMM was developed and learner responses were evaluated to determine the impact of education
- Qualitative study of patient perspectives on B-cell non-Hodgkin lymphoma: Impact of patient education (Abstract Number: e18109) A qualitative study explored the impact of an online, patient-focused education activity on B-cell NHL developed by the Leukemia and Lymphoma Society, University of Nebraska, and PlatformQ Health, to improve patient knowledge on B-cell NHL and offer strategies to enhance quality of life through better disease and side effect management.
- Enhancing clinician confidence on the therapeutic management of non-small cell lung cancer (NSCLC) through continuing medical education (CME) (Abstract Number e18271) Two CME programs on NSCLC were developed and participant responses were compared between the two, to examine differences in learner confidence and competence regarding the management of NSCLC with targeted therapy.
- The impact of continuing medical education (CME) programs in metastatic castration-resistant prostate cancer (CRPC) (Abstract Number e18280) The concurrent development of many CRPC treatments within a short period of time has made prospective data on their sequential use and efficacy complicated, which have challenged clinician confidence, knowledge, and competency.
Attending the 2017 ASCO Annual Meeting?
Stop by our booth in the exhibit hall, booth number 2075 (near the patient advocacy pavilion).
Otherwise, please contact us at info@OMedLive.com for additional information about these abstracts or our outcomes capabilities.